DK0754682T3 - Aminostilbazolderivat og lægemiddel - Google Patents

Aminostilbazolderivat og lægemiddel

Info

Publication number
DK0754682T3
DK0754682T3 DK95914513T DK95914513T DK0754682T3 DK 0754682 T3 DK0754682 T3 DK 0754682T3 DK 95914513 T DK95914513 T DK 95914513T DK 95914513 T DK95914513 T DK 95914513T DK 0754682 T3 DK0754682 T3 DK 0754682T3
Authority
DK
Denmark
Prior art keywords
represents hydrogen
drug
hydroxy
ring
substituted
Prior art date
Application number
DK95914513T
Other languages
Danish (da)
English (en)
Inventor
Hiroyoshi Hidaka
Akira Matsuura
Original Assignee
Western Therapeutics Inst D
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Therapeutics Inst D, Nippon Shinyaku Co Ltd filed Critical Western Therapeutics Inst D
Application granted granted Critical
Publication of DK0754682T3 publication Critical patent/DK0754682T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DK95914513T 1994-04-06 1995-04-05 Aminostilbazolderivat og lægemiddel DK0754682T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6825294 1994-04-06
PCT/JP1995/000658 WO1995027699A1 (en) 1994-04-06 1995-04-05 Aminostilbazole derivative and medicine

Publications (1)

Publication Number Publication Date
DK0754682T3 true DK0754682T3 (da) 2002-02-04

Family

ID=13368389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95914513T DK0754682T3 (da) 1994-04-06 1995-04-05 Aminostilbazolderivat og lægemiddel

Country Status (14)

Country Link
US (1) US5972976A (cg-RX-API-DMAC7.html)
EP (1) EP0754682B9 (cg-RX-API-DMAC7.html)
JP (1) JP3080405B2 (cg-RX-API-DMAC7.html)
KR (1) KR100293867B1 (cg-RX-API-DMAC7.html)
CN (1) CN1053658C (cg-RX-API-DMAC7.html)
AT (1) ATE207057T1 (cg-RX-API-DMAC7.html)
CA (1) CA2187214C (cg-RX-API-DMAC7.html)
DE (1) DE69523298T2 (cg-RX-API-DMAC7.html)
DK (1) DK0754682T3 (cg-RX-API-DMAC7.html)
ES (1) ES2165911T3 (cg-RX-API-DMAC7.html)
PT (1) PT754682E (cg-RX-API-DMAC7.html)
RU (1) RU2138482C1 (cg-RX-API-DMAC7.html)
TW (1) TW308586B (cg-RX-API-DMAC7.html)
WO (1) WO1995027699A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072688B1 (en) * 1998-04-15 2004-06-30 Hiroyoshi Hidaka Method for in vivo detecting a target protein gene by a drug
AU3895299A (en) * 1998-05-12 1999-11-29 Wen Y Chen Use of anti-prolactin agents to treat proliferative conditions
JP3849428B2 (ja) * 1999-04-23 2006-11-22 日本新薬株式会社 微粉化法
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
DE60034963D1 (de) * 1999-12-14 2007-07-05 Nippon Shinyaku Co Ltd Heterocyclische derivate und arzneistoffe
JP2004359545A (ja) * 2001-03-08 2004-12-24 D Western Therapeutics Institute 抗癌剤耐性克服剤
US6967211B2 (en) * 2001-04-10 2005-11-22 Nippon Shinyaku Co. Ltd. Remedial agent for chronic articular rheumatism
US7148244B2 (en) 2001-04-26 2006-12-12 Nippon Shinyaku Co. Ltd. Medicines in controlling Vpr function
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
FR2838437B1 (fr) * 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
AU2003261951A1 (en) * 2002-09-06 2004-03-29 D. Western Therapeutics Institute Medicinal composition and method for treating malignant tumor and utilization thereof
WO2006078941A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
US20100198262A1 (en) * 2009-01-30 2010-08-05 Mckinley Laurence M Axial offset bone fastener system
MX2015014470A (es) * 2013-04-19 2016-02-22 Univ Arkansas Analogos de combretastatina.
EP3080057B1 (de) 2013-12-13 2019-03-20 EuroChem Agro GmbH Nitrifikationsinhibitor enthaltende düngemittelmischung
AU2015240880A1 (en) 2014-03-31 2016-09-15 Bioventures, Llc Disubstituted triazole analogs
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
WO2018144910A1 (en) 2017-02-02 2018-08-09 Bioventures, Llc Methods of protecting against neurodegeneration
CN112110829B (zh) * 2019-06-19 2023-08-01 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
JP2692467B2 (ja) * 1991-12-09 1997-12-17 ダイキン工業株式会社 空調制御装置の電力供給装置
DE69221290T2 (de) * 1991-12-10 1998-01-15 Shionogi & Co Auf aromatischen sulfonamiden basierende hydroxamsäurederivate

Also Published As

Publication number Publication date
KR100293867B1 (ko) 2001-09-17
EP0754682A4 (en) 1998-03-04
RU2138482C1 (ru) 1999-09-27
EP0754682B9 (en) 2003-09-17
WO1995027699A1 (en) 1995-10-19
KR970702253A (ko) 1997-05-13
ATE207057T1 (de) 2001-11-15
EP0754682A1 (en) 1997-01-22
JP3080405B2 (ja) 2000-08-28
PT754682E (pt) 2002-03-28
CA2187214A1 (en) 1995-10-19
CN1145066A (zh) 1997-03-12
TW308586B (cg-RX-API-DMAC7.html) 1997-06-21
MX9604540A (es) 1997-09-30
EP0754682B1 (en) 2001-10-17
DE69523298T2 (de) 2002-06-27
CN1053658C (zh) 2000-06-21
US5972976A (en) 1999-10-26
ES2165911T3 (es) 2002-04-01
DE69523298D1 (de) 2001-11-22
CA2187214C (en) 2002-03-12

Similar Documents

Publication Publication Date Title
DE69523298D1 (de) Aminostilbazolderivate und medikament
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
NO992549L (no) Sukkerforbindelse, geleringsmiddel og fremgangsmåte for fremstilling derav
PT787726E (pt) Novo composto, processo para a sua producao e agente tumoral
PT918776E (pt) Sintese total de acilfulvenos antitumorais
PT87700A (pt) Process for the preparation of a new pyrazolopyridine compound
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
DE3869907D1 (de) Chinolincarbonsaeure-derivate.
ATE324362T1 (de) Neue vinylbenzolderivate
ATE232528T1 (de) Pyrimidinylpyrazolderivate
ATE248814T1 (de) 16-ene-vitamin d derivate
MY130817A (en) Herbicides
ATE337300T1 (de) Hydroxylierte indirubinderivate
FI915025A0 (fi) 8-azabicyklo(3,2,1) oktylalkyltiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ATE24915T1 (de) Synergistin-derivate und ihre herstellung.
FI951505A0 (fi) Uusi 7-subtituoitu oksa- tai atsasteroidiyhdiste
FI935399L (fi) N-substituerade azabicykloheptanderivat samt deras framstaellning och anvaendning